Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Adherence to Varenicline and Abstinence Rates for Quitting Smoking in a Private Health Promotion Center-Based Smoking Cessation Clinic

  • Lee, Jin-Young (Center for Health Promotion, Samsung Medical Center) ;
  • Kim, Min-Ji (Biostatistics Unit, Samsung Biomedical Research Institute, Samsung Medical Center) ;
  • Jun, Hee-Jung (Center for Health Promotion, Samsung Medical Center) ;
  • Kang, Mi-Ra (Center for Health Promotion, Samsung Medical Center) ;
  • Park, Ah-Rham (Center for Health Promotion, Samsung Medical Center) ;
  • Oh, Dae-Eun (Center for Health Promotion, Samsung Medical Center) ;
  • Choi, Yoon-Ho (Center for Health Promotion, Samsung Medical Center) ;
  • Hwang, Jung-Hye (Center for Health Promotion, Samsung Medical Center)
  • Received : 2011.11.02
  • Accepted : 2012.03.26
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Varenicline is an effective smoking cessation aid. However, smokers prescribed with varenicline do not always receive varenicline for 12 weeks, as recommended. This study analyzed the subjects who received varenicline and investigated the effect of varenicline treatment duration on the success rate of 6-month smoking cessation. Methods: This study retrospectively analyzed 78 subjects, who received varenicline, out of the 105 smokers that had visited the smoking cessation clinic after medical examination from September 2007 to December 2009. Results: The subjects were all males. Twenty-two subjects (28.2%) had varenicline treatment for 12 weeks or longer; 18 subjects (23.1%) for 8~12 weeks; 22 subjects (28.2%) for 4~8 weeks; and 16 subjects (20.5%) for less than 4 weeks. The total success rate of the 6-month smoking cessation was 47.4%. The success rate of the 6-month smoking cessation was 63.6% in the group that received varenicline for 12 weeks or longer, which was higher than 41.1% of the group that early terminated the varenicline treatment (p=0.074). The period of varenicline treatment was extended for one more week, the odds ratio of the 6-month smoking cessation success increased to 1.172-folds (p=0.004; 95% confidence interval, 1.052~1.305). Adverse events occurred in 30.8% of the subjects who received varenicline, but no serious adverse events were found. Conclusion: If varenicline treatment period is extended, the odds ratio of the success rate for the 6-month smoking cessation increases. Therefore, an effort to improve drug compliance for varenicline in clinical practices could be helpful for the long-term success of smoking cessation.

Keywords

References

  1. Action on Smoking and Health. Smoking statistics: illness and death [Internet]. London: Action on Smoking and Health; 2011 [cited 2011 Oct 23]. Available from: http://www.ash.org.uk/files/documents/ASH_107.pdf.
  2. Kim IS, Jee SH, Ohrr H, Yi SW. Effects of smoking on the mortality of lung cancer in Korean men. Yonsei Med J 2001;42:155-60. https://doi.org/10.3349/ymj.2001.42.2.155
  3. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. The Forth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008. Seoul: Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention; 2009 [cited 2011 Oct 23]. Available from: http://knhanes.cdc.go.kr/.
  4. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000;2:19-37. https://doi.org/10.1080/14622200050011277
  5. Zbikowski SM, Swan GE, McClure JB. Cigarette smoking and nicotine dependence. Med Clin North Am 2004;88:1453-65, x. https://doi.org/10.1016/j.mcna.2004.07.004
  6. Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs 2006;21:433-6. https://doi.org/10.1097/00005082-200611000-00004
  7. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placeboand bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8. https://doi.org/10.1001/archinte.166.15.1561
  8. Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother 2007;7:121-7. https://doi.org/10.1586/14737175.7.2.121
  9. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29:1027-39. https://doi.org/10.1016/j.clinthera.2007.06.011
  10. Kang YS, Choi SY, Ryu E. The effectiveness of a stress coping program based on mindfulness meditation on the stress, anxiety, and depression experienced by nursing students in Korea. Nurse Educ Today 2009;29: 538-43. https://doi.org/10.1016/j.nedt.2008.12.003
  11. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997;96:3243-7. https://doi.org/10.1161/01.CIR.96.9.3243
  12. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-94. https://doi.org/10.1136/bmj.298.6676.789
  13. Critchley JA, Capewell S. Mortality risk reduction asso ciated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97 https://doi.org/10.1001/jama.290.1.86
  14. Enstrom JE, Heath CW Jr. Smoking cessation and mortality trends among 118,000 Californians, 1960-1997. Epidemiology 1999;10:500-12. https://doi.org/10.1097/00001648-199909000-00007
  15. Molyneux A. Nicotine replacement therapy. BMJ 2004; 328:454-6. https://doi.org/10.1136/bmj.328.7437.454
  16. Fiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, et al. Methods used to quit smoking in the United States. Do cessation programs help? JAMA 1990;263:2760-5. https://doi.org/10.1001/jama.1990.03440200064024
  17. Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 2004;5:55-65. https://doi.org/10.1038/nrn1298
  18. Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009;31: 463-91. https://doi.org/10.1016/j.clinthera.2009.03.021
  19. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained- release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296: 47-55. https://doi.org/10.1001/jama.296.1.47
  20. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63. https://doi.org/10.1001/jama.296.1.56
  21. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71. https://doi.org/10.1001/jama.296.1.64
  22. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009;14:384-92. https://doi.org/10.1111/j.1440-1843.2008.01476.x
  23. Song B, Yun WS, Choi EY, Cheong YS, Park EW. Smoking cessation rate and related factors of varenicline in clinical practice. Korean J Fam Med 2011;32: 112-9. https://doi.org/10.4082/kjfm.2011.32.2.112

Cited by

  1. Effectiveness of Smoking Cessation Using Motivational Interviewing in Patients Consulting a Pulmonologist vol.76, pp.6, 2012, https://doi.org/10.4046/trd.2014.76.6.276
  2. Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment vol.50, pp.5, 2012, https://doi.org/10.3109/10826084.2014.991405
  3. Compliance and Effectiveness of Smoking Cessation Program Started on Hospitalized Patients vol.37, pp.3, 2012, https://doi.org/10.4082/kjfm.2016.37.3.149
  4. A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme vol.15, pp.1, 2017, https://doi.org/10.1186/s12971-017-0116-0
  5. Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers vol.20, pp.10, 2012, https://doi.org/10.1093/ntr/ntx210
  6. Predictors of Adherence to Smoking Cessation Medications among Current and Ex-Smokers in Australia: Findings from a National Cross-Sectional Survey vol.18, pp.22, 2021, https://doi.org/10.3390/ijerph182212225